Evidence supporting the potential contribution of targeted radiotherapy to the management of neuroendocrine tumours is now strong. Acting systemically, this is an effective option for patients with inoperable or multi-site disease. Toxicity is generally low, being limited to reversible myelosuppression and theoretical nephrotoxicity. Prerequisites for treatment success include demonstration of high tumour uptake relative to non-target tissues on quantitative diagnostic radionuclide imaging and stable haematological and biochemical function. In addition to (131)I metaiodobenzylguanidine therapy, which is now well established, there is growing interest in radiolabelled peptide therapy using a range of somatostatin receptor analogues such as (90)Y DOTATOC and (90)Y lanreotide. The results of clinical experience are summarised and the direction for future research is discussed.
Search Results
David Taïeb, Christelle Fargette, Abhishek Jha, and Karel Pacak
damage to the cell membranes of tumor cells and subsequent apoptosis ( Borgna et al. 2022 ). There is also a lot of exciting work on the combination of targeted radionuclide therapy (TRT) with immunotherapy. The role of TRT would be to allow local
David Taïeb, Abhishek Jha, Giorgio Treglia, and Karel Pacak
responses for more individualized treatment plans, α-emitting isotopes, and combination of targeted radionuclide therapy with other forms of treatment, including immunotherapy. Current classification of PPGL Pheochromocytomas (PHEOs) and
Karel Pacak and Roderick Clifton-Bligh
.1016/j.ccell.2017.01.001 ) 28162975 Goldsmith SJ 2020 Targeted radionuclide therapy: A historical and personal review . Seminars in Nuclear Medicine 50 87 – 97 . ( https://doi.org/10.1053/j.semnuclmed.2019.07.006 ) 31843064 Gupta P Strange K
Michael Lassmann, Christoph Reiners, and Markus Luster
) to explain different cellular survival fractions obtained with a fixed absorbed dose but with different dose rates or dose fractionations. One decade ago, Dale developed the theoretical formulas for calculating BED in targeted radionuclide therapy
Olga Lakiza, Julian Lutze, Alyx Vogle, Jelani Williams, Abde Abukdheir, Paul Miller, Chih-Yi ‘Andy’ Liao, Sean P Pitroda, Carlos Martinez, Andrea Olivas, Namrata Setia, Stephen J Kron, Ralph R Weichselbaum, and Xavier M Keutgen
radiotherapy and targeted radionuclide therapy have demonstrated relatively high objective response rates in PanNETs when compared to other NET subtypes. Here, taking into account both the high incidence of MEN1 mutations in PanNETs and prior studies linking
C Spitzweg, P J Nelson, E Wagner, P Bartenstein, W A Weber, M Schwaiger, and J C Morris
particular in larger tumors in the context of NIS-targeted radionuclide therapy. Due to its high linear energy transfer with short path length, 211 At may also represent a potent alternative radionuclide in the context of NIS gene therapy, in particular in
G A Kaltsas, D Papadogias, P Makras, and A B Grossman
. Journal of Nuclear Medicine 46 (Suppl 1) 62S –66S. Larson SM & Krenning EP 2005 A pragmatic perspective on molecular targeted radionuclide therapy. Journal of Nuclear Medicine 46 (Suppl 1) 1S –3S
Monica Ter-Minassian, Jennifer A Chan, Susanne M Hooshmand, Lauren K Brais, Anastassia Daskalova, Rachel Heafield, Laurie Buchanan, Zhi Rong Qian, Charles S Fuchs, Xihong Lin, David C Christiani, and Matthew H Kulke
Oncology 29 934 – 943 . ( doi:10.1200/JCO.2010.33.2056 ). Kwekkeboom DJ de Herder WW Krenning EP 2011 Somatostatin receptor-targeted radionuclide therapy in patients with gastroenteropancreatic neuroendocrine tumors . Endocrinology and
Tessa Brabander, Wouter A van der Zwan, Jaap J M Teunissen, Boen L R Kam, Wouter W de Herder, Richard A Feelders, Eric P Krenning, and Dik J Kwekkeboom
radiation exposure from peptide receptor radionuclide therapy . Journal of Nuclear Medicine 53 1663 – 1669 . ( doi:10.2967/jnumed.112.107482 ) Forrer F Waldherr C Maecke HR Mueller-Brand J 2006 Targeted radionuclide therapy with 90
